Comment on the choice of TNF inhibitors;Stellungnahme zur präparatewahl bei TNF-inhibitoren

Zeitschrift fur Rheumatologie

Volumn 64, Issue 2, 2005, Pages 88-89

  Manger, B ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG EFFICACY; HUMAN; RHEUMATOID ARTHRITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23844508279     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-005-0708-6     Document Type: Article

References (2)

1. Manger B (2002) Überarbeitete Empfehlungen der Deutschen Gesellschaft für Rheumatologie mit Tumornekrose-faktor-hemmenden Wirkstoffen bei entzündlich rheumatischen Erkrankungen. Z Rheumatol 61:694-697
2. Furst DE et al (2004) Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 63 (Suppl. II):ii2-ii12